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PatientstreatedwithrecombinanthumanEpodemonstrateanimprovementininsulinsensitivity.Weaimedtoinvestigatewhether
CNTO 530, a novel Epo receptor agonist, could aﬀect glucose tolerance and insulin sensitivity. A single administration of CNTO
530 signiﬁcantly and dose-dependently reduced the area under the curve in a glucose tolerance test in diet-induced obese and
diabetic mice after 14, 21, and 28 days. HOMA analysis suggested an improvement in insulin sensitivity, and this eﬀect was
conﬁrmed by a hyperinsulinemic-euglycemic clamp. Uptake of 14C-2-deoxy-D-glucose indicated that animals dosed with CNTO
530 transported more glucose into skeletal muscle and heart relative to control animals. In conclusion, CNTO530 has a profound
eﬀect on glucose tolerance in insulin-resistant rodents likely because of improving peripheral insulin sensitivity. This eﬀect was
observed with epoetin-α and darbepoetin-α, suggesting this is a class eﬀect, but the eﬀect with these compounds relative to
CNTO530 was decreased in duration and magnitude.
1.Introduction
Erythropoietin (Epo) is a glycoprotein hormone secreted by
the kidney and liver into circulation in response to hypoxia
[1].TheprincipalfunctionattributedtoEpoistheregulation
of red blood cell production, mediated by its speciﬁc cell
surface receptor (EpoR) [2]. To this end, recombinant Epo
forms (epoetin-α, epoetin-β, and the long-acting analogue
darbepoetin-α) have been used to treat anemia in chronic
kidney disease and chemotherapy-induced anemia in cancer
patients [3].However, EpoR expression in nonerythroid cells
has raised questions as to additional biological functions of
Epo in nonhaematopoietic tissues. Recent data suggest that
endogenous Epo-EpoR signaling contributes to wound heal-
ing responses, physiological and pathological angiogenesis,
and the body’s innate response to injury in the brain and
heart [4].
Several clinical studies have reported the eﬀect of recom-
binant Epo on glucose metabolism in patients undergoing
hemodialysis. Signiﬁcant improvements in glucose utiliza-
tion, mainly due to attenuation of insulin resistance were
observed in 20 hemodialysis patients after three months of
Epo therapy [5]. Tuzcu et al. found that patients with
end-stage renal disease treated with Epo had a decreased
HOMA index compared to untreated patients, suggesting an
improvement in insulin sensitivity [6]. Glucose and lipid
metabolism were studied in seven patients with end-stage
renal disease being treated with erythropoietin to correct
anemia [7]. This study showed that Epo alleviated insulin
insensitivity and corrected lipid abnormalities in these
patients.
CNTO 530 is a MIMETIBODY that incorporates an
erythropoietin mimetic peptide (EMP-1) genetically fused to
a domain that includes the Fc portion of a human antibody2 Experimental Diabetes Research
(Figure 1). EMP-1 is a 20 amino acid peptide that binds
and activates the Epo receptor [8, 9]. Signiﬁcant engineering
eﬀorts in designing CNTO 530 resulted in a molecule where
divalent display of EMP-1 peptides allows for the peptides
to associate through a covalent interaction and activate the
EpoR. The terminal half-life of CNTO 530 is suﬃciently
longer than the EMP-1 peptide in rodents [10] (40hrs versus
4hrs) which enables sustained activation of the EpoR. [10,
11]. As anticipated, this translates to a sustainable pharma-
codynamic proﬁle in mice. A single subcutaneous dose of
CNTO 530 caused a long-lived stimulation of erythropoiesis
that translated to increased hemoglobin values that were
maintained for more than three weeks [10].
Here we report that CNTO 530, epoetin-α, and darbe-
poetin-α dose-dependently improved glucose tolerance in
DIO mice. A hyperinsulinemic-euglycemic clamp study
showed a beneﬁcial eﬀect of CNTO 530 in improving
insulin sensitivity in diabetic mice. This eﬀect was at least
partially mediated via stimulation of insulin-dependent
glucose transport into skeletal muscle. To our knowledge,
this is the ﬁrst time an increase in insulin-dependent glucose
utilization in skeletal muscle has been demonstrated for an
Epo receptor agonist.
2.MaterialsandMethods
2.1. Mice. All animal studies were performed according to
the National Research Council’s Guide for the Care and Use
of Laboratory Animals and were approved by an internal
IACUC. C57Bl/6J mice were maintained on a diet containing
60.9% kcal from fat (Purina TestDiets 58126, Richmond,
IN) beginning at 4 weeks of age and all animals used in
the DIO studies achieved three consecutive weeks of fasting
blood glucose levels above 120 mg/dL. Lean littermates were
maintained on a normal chow diet (Purina TestDiets 5010).
S t u d i e sw e r ec o m p l e t e dw h e na n i m a l sw e r e1 6 – 2 0w e e k so f
age.
2.2. Intraperitoneal Glucose Tolerance Test. Male DIO mice
were randomized based on fasting blood glucose (FBG) fol-
lowing a 16-hour fast. Mice were dosed IV with phosphate-
buﬀered saline (PBS), CNTO 530, epoetin-α,d a r b e p o e t i n α,
or CNTO1996 (a negative control protein identical to CNTO
530 but lacking the EMP-1 peptides). On the day of the
glucose tolerance test, mice were given an intraperitoneal
injection (1mg/g) of glucose (Sigma). Blood glucose mea-
surements were made 15, 30, 60, 90, 120, and 180 minutes
following dosing using a hand-held glucometer (OneTouch
Basic, LifeScan, Skilman, NJ).
2.3. Hematology and Insulin Measurements. Blood was col-
lected into EDTA-treated tubes via a cardiac puncture from
euthanized mice. Hematological analysis was completed
immediately using an ADVIA 120 Analyzer (Siemens Med-
ical Solutions Diagnostics, Tarrytown, NY). An additional
aliquot of blood was centrifuged, and plasma was isolated.
Plasmasampleswerefrozenat–80◦Cuntilanalysisbyinsulin
ELISA (Crystal Chem Inc., Downers Grove, IL).
EMP-1 peptide
Linker
Engineered IgG4
Figure 1: Schematic of CNTO 530. The schematic outlines the
structure of CNTO 530 including the engineered Fc (CH2 and CH3
domains), a linker containing a partial VH region, and two EMP-1
peptides.
2.4. Conversion of mg/kg Doses with Epo-R Agonists to U/kg.
Equation (1) was used to calculate UT-7 rHuEPO equiva-
lents:
UT-7Units/μg = (Mol wt of ERA) ∗
C
(EC50 for ERA)
,
(1)
where
C =

120Units/μg

∗
(EC50 for rHuEPO)
34kD
. (2)
And EC50 for ERA is 50% maximally eﬀective concentration
foranerythropoietin receptoragonist(molarconcentration)
in the UT7 viability assay [10].
Therefore, the doses in mg/kg were converted to U/kg by
multiplying the respective dose (mg/kg) by the in vitro activ-
ity of each compound (epoetin-α = 120U/μg; darbepoetin-α
= 199U/μg; CNTO 530 = 30U/μg).
2.5. Homeostasis Model Assessment (HOMA) Analysis. DIO
mice were fasted overnight and randomized based on FBG
a n db o d yw e i g h t .M i c ew e r ei n j e c t e dI Vw i t hP B So r
CNTO 530 (0.3mg/kg). Fourteen days after dosing, mice
were fasted overnight (16hrs) and blood was collected
into tubes treated with EDTA via cardiac puncture. Fasting
glucose levels were measured using a glucose oxidase reagent
(Thermo Electron Corporation, Waltham, MA) according to
the manufacturer’s instructions. Fasting insulin levels were
measured using the Mouse Ultra-Sensitive Insulin ELISA Kit
(Crystal Chem Inc., Downers Grove, IL) according to theExperimental Diabetes Research 3
manufacturer’s instructions. The HOMA index was calcu-
lated using (3)[ 12]:
HOMA =

fasting insulin (mIU/L) ∗ fasting glucose (mmol/L)

22.5
.
(3)
2.6. Validation of Glucometer Values. The studies reported
heremonitortheeﬀectofCNTO530onglucosemetabolism.
CNTO 530 is an EpoR agonist that increases hematocrit
(Hct) levels in a sustainable manner. It was previously
reported that plethoric Hct values can inﬂuence the results
obtained with a glucometer [13]. Many of the hand-held
glucometer devices contain warnings that extreme hemat-
ocrit values can cause false glucose readings. To address the
concernthattheobservedglucoselevelscouldbetheresultof
an artifact, a study comparing blood glucose measurements
was completed using mice with elevated Hct levels. DIO
mice were dosed with either CNTO 530 (0.3mg/kg) or
PBS, and whole blood and plasma were isolated fourteen
days later after an overnight fast. Blood glucose levels were
measured using a hand-held glucometer and with a VetAce
Clinical Chemistry System (Alfa Wassermann Inc.) while
plasma glucose was measured using a hand-held glucometer
(OneTouch Basic, LifeScan), a VetAce instrument, and a glu-
cose oxidase assay. CNTO 530-treated animals consistently
decreased blood and plasma glucose level relative to control
mice independent of the measurement method used (data
not shown).
2.7. Hyperinsulinemic-Euglycemic Clamp Studies. C57Bl/6J
male mice (6 weeks of age) were maintained on a semisyn-
thetic high-fat diet (purina test diet no. 58126) for 14 weeks.
Prior to the start of the study, the animals were randomized
into 6 groups (n = 12) by body weight, fasting blood
glucose, and fasting insulin. All animals were dosed IV with
CNTO 530 (0.03 or 0.3mg/kg) or PBS under isoﬂurane
anesthesia. The animals remained on the same high-fat diet
until the hyperinsulinemic-euglycemic clamp analysis was
performed. The three groups (PBS, 0.03mg/kg, 0.3mg/kg)
were subjected to clamp analysis one day after dosing, and
the remaining three groups (PBS, 0.03mg/kg, 0.3mg/kg)
were clamped 14 days after dosing. Blood hemoglobin was
measuredonthedayofclampanalysis.Bodyweightandfood
intake was obtained weekly. Glucose levels were measured
using the Freestyle Blood Glucose Measurement System
from Memo Medical Mail Organization (Amersfoort, The
Netherlands) according to the manufacturer’s instruction.
Plasma insulin was measured using the Ultrasensitive Mouse
Insulin ELISA kit (Mercodia, Uppsala, Sweden) according to
the manufacturer’s instruction.
The clamp analysis was performed as described pre-
viously [14]. Brieﬂy, animals were fasted for 16 hrs,
anesthetized with acepromazine (6.25mg/kg), midazolam
(6.25mg/kg), and fentanyl (0.3125mg/kg), and an infusion
needle was placed in one of the tail veins. Basal rates of
glucose turnover were determined by means of a primed
(0.7μCi), continuous (1.2μCi/h) infusion of [3H]-glucose
for 60 minutes. Blood samples to determine basal glucose
turnover were taken 50 and 60 minutes after the start of
the infusion. The hyperinsulinemic condition was started
with a bolus (7.0mU), followed by continuous infusion
of insulin (Actrapid, Novo Nordisk, 11.7mU/h) and [3H]-
glucose. A variable infusion of 12.5% unlabeled D-glucose
solution was applied to maintain euglycemia as measured
from blood samples (every 10min) taken by tail bleeding.
During the clamp (70, 80, and 90 minutes after the start
of the insulin infusion), blood samples were drawn to
determine glucose concentration and dpm of [3H]-glucose.
Plasma for [3H]-glucose determinations was deproteinized
by TCA precipitation. For each sample, an aliquot of the
supernatant was counted directly and another was dried
to remove 3H2O. To assess glucose oxidation at basal and
hyperinsulinemic state, 3H2O level in plasma was calculated
as the diﬀerence between dried and undried samples. At
90 minutes, additional samples were collected to determine
insulin concentration. To estimate insulin-stimulated glu-
cose uptake in individual tissues, 2-deoxy-D-[14C] glucose
was administered as a bolus (2μCi) 40 minutes before the
end of the clamp. After sacriﬁce, liver, muscle (upper hind
leg and heart) and adipose tissue (visceral and epididymal)
were removed, immediately frozen in liquid N2,a n ds t o r e d
at −20◦C until further analysis. Measurement of tissue-
speciﬁc 2-deoxy-D-[14C]-glucose was used to determine
glucose uptake. For this analysis, part of the muscle and
adipose tissue sample was homogenized (∼10% wet wt/vol)
in H2O. The homogenate was boiled, and the supernatant
was subjected to an ion-exchange column to separate 2-
deoxy-D-[14C]-glucose-6-P from 2-deoxy-D-[14C]-glucose.
Radioactivity in the 2-deoxy-D-[14C]-glucose-6-P fraction
represented the glucose taken up by the tissue.
2.8. Clamp Data Analysis. Signiﬁcance of diﬀerence of
values obtained were calculated using a nonparametric test
for independent samples, Mann-Whitney U-test, using the
computer program SPSS.
3. Results and Discussion
3.1. Glucose Tolerance Test at Various Times following Dosing.
DIO mice were treated with a single IV dose of CNTO 530
(0.3mg/kg), and glucose metabolism was monitored using
an intraperitoneal glucose tolerance test (IPGTT) at various
times following dosing (day 1 to 35). CNTO 530 did not
inﬂuence glucose tolerance 24 hours after dosing. However,
a signiﬁcant improvement was observed in both fasting
glucose(179±29versus133±19mg/dLforuntreatedversus
treated)andoverallglucosetolerancesevendaysafterasingle
dose of CNTO 530 (Figure 2(b)). In a separate study, the
activity of CNTO 530 was compared to a control protein
that lacked the EMP-1 peptides to ensure that the observed
eﬀects were due to the peptide and not the Fc. The glucose
lowering eﬀect was not observed in the mice treated with
the protein lacking the EMP-1 peptides (data not shown).
Fasting blood glucose remained improved in the treated4 Experimental Diabetes Research
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Figure 2: Single dose of CNTO 530 improves glucose tolerance and increases hemoglobin levels in DIO mice. (a) DIO mice (n = 7) were
dosed IV with CNTO 530 (0.3 mg/kg) or PBS (), and an IPGTT was done after 14 days. (b) IPGTT was done at various days following a
single dose of CNTO 530 (0.3mg/kg). The data were analyzed to determine the area under the curve (AUC) for CNTO 530-treated ()a n d
PBS-treated () groups (n = 7). The AUC is plotted versus time. (c) The hemoglobin (g/dL) measured at various times following a single
dose of CNTO 530 (0.3mg/kg) was plotted versus time. The results are presented as mean ± SEM. ∗indicates a P value < .05. ∗∗indicates a
P value <.01. ∗∗∗indicates a P value < .005.
animals 14 and 21 days after CNTO530 treatment, but was
similartotheuntreatedgroupafter35days(datanotshown).
The area under the curve (AUC) for the glucose tolerance
tests showed a signiﬁcant improvement with CNTO 530
treatment on days 7, 14, 20, and 28 (Figure 2(b)). The most
dramatic eﬀect on glucose tolerance following CNTO 530-
treatment was observed on day 14 where glucose was cleared
from circulation by the 15-minute time point (Figure 2(a)).
CNTO 530-mediated acceleration of glucose utilization was
diminished but still signiﬁcant by day 28 and not seen by day
35 (Figure 2(b)). Hemoglobin levels followed a similar time-
dependent change, showing an increase that peaked on day
2 2a n dr e t u r n e dt on o r m a ll e v e l sb yd a y2 9( Figure 2(c)).
Similar studies were completed in lean littermate mice
fed a normal chow diet. Mice (n = 7) were given a single
administration of CNTO 530 (0.01–0.3mg/kg), and glucose
tolerance tests were completed after 1 and 14 days. As we
observed in the diabetic rodents, no signiﬁcant changes were
seen in glucose clearance 24 hours after dosing. However,
there were signiﬁcant improvements in the area under the
curve in the glucose tolerance test in animals dosed with
0.3 and 0.1mg/kg CNTO 530 as compared to PBS (22865.4
± 1900.2, 24478.9 ± 1093.4, and 28773.2 ± 1368.3, resp.,
mean ±SEM).Therewerenodose-dependentchangesinthe
fasting blood glucose.
3.2. Glucose Tolerance Test-Dose Titration. To determine
whether the eﬀect of CNTO 530 on glucose tolerance was
dose dependent, GTTs were repeated in DIO mice fourteen
daysafterIVdosingwithincreasingconcentrationsofCNTO
530 (0.01, 0.03, 0.1, 0.3mg/kg). A dose-dependent reduction
in the AUC was observed with 0.03, 0.1, and 0.3mg/kg
whereas a dose of 0.01 mg/kg had no eﬀect (Figures 3(a) and
3(b)).
3.3. Glucose Tolerance Test with Other EpoR Agonists. CNTO
530 is an agonist to the EpoR, yet there is no homology
between the molecular structure of CNTO 530 and that ofExperimental Diabetes Research 5
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Figure 3: Dose response of CNTO 530 at day 14. PBS () or CNTO 530 was dosed IV at increasing concentrations (0.01,0 . 0 3 ,0 . 1  ,
0.3)i nD I Om i c e( n = 5). (a) Fourteen days after dosing, an IPGTT was performed. (b) The AUC from part A was plotted for each dose of
CNTO 530. The results are presented as mean ± SEM. ∗∗indicates a P value < .01. ∗∗∗indicates a P value < .005.
Epo itself. Therefore, there is the potential that either the
EMP-1 peptide or the Fc domain of the molecule interacts
with a diﬀerent receptor entirely, thereby eﬀecting glucose
metabolism through a receptor other than the EpoR. To
address this point, similar glucose tolerance studies were
repeated with epoetin-α and darbepoetin-α.T oc o m p a r e
the pharmacodynamic eﬀects of diﬀerent EpoR agonists, an
equipotent dose of each molecule was used (see Section 2.4).
In addition, the GTTs were conducted 5 and 7 days
after dosing for epoetin-α and darbepoetin-α,r e s p e c t i v e l y ,
given that this is the time when hemoglobin levels are
maximally elevated in rodents [11]. Similar to CNTO 530,
epoetin-α and darbepoetin-α increased glucose clearance in
a dose-dependent manner (Figure 4(a) and data not shown).
However, the maximal reduction in AUC during a GTT was
not as profound relative to CNTO 530, suggesting that the
extended pharmacokinetic proﬁle observed with CNTO 530
contributes to an improved pharmacodynamic glucose eﬀect
(Figure 4(b)).
3.4. HOMA Analysis. Homeostasis model assessment
(HOMA) is a rather indirect way to assess insulin sensitivity,
as it is less invasive and less time consuming relative to clamp
analysis [12] HOMA was initially used to determine if there
was a gross change in insulin sensitivity in DIO mice treated
with CNTO 530. Fasting glucose and insulin levels in CNTO
530-treated mice were signiﬁcantly reduced compared to the
PBS-treated control 14 days after IV dosing (Figures 5(a)
and 5(b)). As a result, CNTO 530 decreased the calculated
HOMA index more than 10-fold relative to control animals,
suggesting a signiﬁcant improvement in insulin sensitivity
(Figure 5(c)).
3.5. Hyperinsulinemic Clamp. To delineate the CNTO 530
mechanism of reducing blood glucose, we performed a
hyperinsulinemic-euglycemic clamp in anesthetized DIO
mice. C57/Bl6 mice were maintained on a high-fat diet for
14 weeks prior to the CNTO 530 treatment to induce obesity
and insulin resistance (mean BW 45.7 ± 3.5g, mean fasting
insulin 3.8 ± 3.3ng/mL, mean fasting blood glucose 120.6 ±
18mg/dL). The clamp was performed one and fourteen days
following a single IV dose of vehicle or CNTO 530 (0.03 and
0.3mg/kg).
In agreement with previous studies, no signiﬁcant chan-
gesinhemoglobinorFBGwer edet ect edoneda yaft erCNT O
530 administration (Table 1). Fourteen days after treatment,
however, both doses of CNTO 530 signiﬁcantly increased
hemoglobin (Table 1). CNTO 530 (0.3mg/kg) signiﬁcantly
reduced fasting blood glucose fourteen days after treatment,
consistent with the previous studies (Table 1). Administra-
tionofCNTO530didnotalterbodyweight(Table 1)orfood
intake (data not shown).
During the clamp studies, the circulating levels of glu-
cose and the diﬀerence in plasma insulin levels were not
statistically diﬀerent between the groups (Table 1). The
glucose infusion rate (GIR) required to maintain the target
glucose concentration during the clamp study was not
signiﬁcantly diﬀerent between the groups one day after
CNTO 530 administration, although there was a tendency
towards a higher GIR in animals treated with the high
dose of CNTO 530 (0.3mg/kg) relative to the control group
(Table 1). However, GIR was signiﬁcantly increased (2.2-
fold) in DIO mice 14 days after administration of the 0.3
mg/kg dose of CNTO 530 (Figure 6(a), Table 1). Hepatic
glucose production (HGP), measured by the isotope dilution
of the infused [3H]-glucose, was not diﬀerent between the
treatment groups with the exception of an increased basal
HGP detected in mice treated with CNTO 530 (0.3mg/kg)
one day after IV injection (Table 1). Consistent with GIR
changes, the rate of whole-body glucose disappearance was
signiﬁcantly elevated in the CNTO 530 (0.3mg/kg) groups
by 40% and 50% after one and fourteen days after treatment,6 Experimental Diabetes Research
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later, (a) FBG and (b) fasting insulin levels were measured. (c) HOMA analysis was calculated for each group. The results are presented as
mean ± SEM. ∗indicates a P value < .05. ∗∗∗indicates a P value < .005.
respectively(Table 1).Whole-bodyglucoseoxidationdidnot
change between the groups at basal or hyperinsulinemic
state (Table 1). Insulin-stimulated glucose transport activity
in skeletal muscle, heart, and adipose tissues was estimated
by monitoring the rate of whole-body clearance of 2-
deoxyglucose and its rate of phosphorylation during the
last 40 minutes of the insulin clamp. Since 2-deoxyglucose
is transported into tissue and is phosphorylated but not
further metabolized, determination of the tissue content of
2-deoxyglucose-6-phosphate can be used to produce a valid
estimateoftherateofglucosetransportandphosphorylation
in individual tissues. Hyperinsulinemic glucose transport
activity in skeletal muscle and heart was signiﬁcantly
increased by approximately 30% and 50%, respectively, in
CNTO 530-treated (0.3 mg/kg) mice compared to control
mice 14 days after dosing (Figures 6(c) and 6(d), Table 1).
CNTO 530 (0.3mg/kg) administration resulted in increased
insulin-stimulated glucose transport in visceral adipose by
25% and 64% after one and fourteen days of dosing
respectively, but these diﬀerences did not achieve statistical
signiﬁcance (Figure 6(e), Table 1). No change in insulin-
stimulated glucose transport was detected in epididymal
adipose tissue between the groups (Figure 6(f), Table 1).
Clinicaltrialdatahaveshownthatpatientswhoseanemia
is treated with recombinant human Epo often exhibit im-
proved peripheral insulin sensitivity, although the mecha-
nism of action for this is unclear. For example, Mak [15]
has suggested that the improvement in insulin sensitivity in
dialysis patients treated with EPO is a direct eﬀect of the
correction of the anemia associated with kidney failure.
Other authors suggest that erythropoietin increases the
oxygen supply to tissues and have shown a strong corre-
lation between pO2 and peripheral insulin sensitivity [16].
However, there are contradicting studies that suggest that
the changes in insulin sensitivity are not directly linked
to hematocrit levels or oxygen capacity. One such study
monitored insulin sensitivity via an euglycemic insulin
clamp and showed that patients treated with Epo exhibited
improved insulin sensitivity and glucose clearance before
hematocrit began to increase [17]. Another study suggestedExperimental Diabetes Research 7
PBS 0.3mg/kg
0
10
20
30
40
50
60
70 ∗∗∗
G
I
R
(
µ
m
o
l
/
m
i
n
.
k
g
)
(a)
PBS 0.3mg/kg
∗∗∗
Glucose uptake day 14
0
20
40
60
80
G
l
u
c
o
s
e
u
p
t
a
k
e
(
µ
m
o
l
/
m
i
n
.
k
g
)
(b)
PBS 0.3mg/kg
Muscle-day 14
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8 ∗
G
l
u
c
o
s
e
u
p
t
a
k
e
(
µ
m
o
l
/
g
t
i
s
s
u
e
)
(c)
PBS 0.3mg/kg
0
1
2
3
4
5
6
∗∗
G
l
u
c
o
s
e
u
p
t
a
k
e
(
µ
m
o
l
/
g
t
i
s
s
u
e
)
(d)
PBS 0.3mg/kg
Visceral fat-day 14
0
0.2
0.4
0.6
0.8
1
1.2
1.4
G
l
u
c
o
s
e
u
p
t
a
k
e
(
µ
m
o
l
/
g
t
i
s
s
u
e
)
(e)
PBS 0.3mg/kg
0
0.2
0.4
0.6
Epididemal fat-day 14
G
l
u
c
o
s
e
u
p
t
a
k
e
(
µ
m
o
l
/
g
t
i
s
s
u
e
)
(f)
Figure 6: Hyperinsulinemic-euglycemic clamp following a single dose of CNTO 530. (a) The glucose infusion rate in DIO mice treated IV
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tissues in DIO mice treated IV with CNTO 530 (0.3mg/kg) or PBS measured fourteen days after drug administration. A nonhydrolyzable,
radiolabeled glucose molecule was dosed as a bolus to the animals 40 minutes before the end of the clamp. The amount of glucose taken up
into the skeletal muscle (c), the heart (d), the visceral fat (e), and the epididymal fat (f). ∗indicates a P value < .05. ∗∗∗indicates a P value
< .005.
that Epo treatment increased insulin sensitivity by reducing
iron stores and improving the chronic inﬂammatory state of
dialysis patients [18].
The role of Epo signalling in glucose metabolism and
insulin resistance has also been studied in murine models.
In an STZ-model of diabetes in NOD-SCID mice, treatment
with either rhEpo or CEPO had no eﬀect on insulin sensi-
tivity [19]. However, this may not be an appropriate animal
model since most of the islets in the STZ-treated animals
would be destroyed and insulin levels would likely be low.
In a more relevant study, Epo receptor-null mice that were
rescued with EpoR expression restricted to hematopoietic
tissue developed obesity and glucose intolerance compared
tocontrolmice[20].ThisstudyclearlysuggestsaroleforEpo
receptor signaling in nonhematopoietic tissues in regulating
glucose metabolism and insulin sensitivity. Finally, several
weeks of dosing epoetin-α resulted in improved glucose
levels in multiple murine models type 2 diabetes including8 Experimental Diabetes Research
Table 1: Hyperinsulenemic euglycemic clamp characteristics in DIO mice treated with single IV administration of CNTO 530 (0.03mg/kg
and 0.3mg/kg). Insulin clamp was performed at one and fourteen days after drug administration. The results are presented as mean ± SEM.
#indicates a P value < .05 relative to control group.
Day 1 Day 14
PBS 0.03mg/kg 0.3mg/kg PBS 0.03mg/kg 0.3mg/kg
Body weight, g 45.7 ± 1.5 46.6 ± 1.7 44.7 ± 1.8 46.9 ± 1.5 43 ± 4.8 42.9 ± 4.8
Hemoglobin, mmol/L 8.6 ± 0.3 8.4 ± 0.5 8.4 ± 0.3 9.3 ± 0.3 10.0 ± 0.2# 11.3 ± 0.2#
Fasting glucose, mmol/L 5.5 ± 0.3 5.4 ± 0.4 5.5 ± 0.6 4.7 ± 0.4 4.5 ± 0.3 2.8 ± 0.15#
Fasting plasma insulin, ng/mL 1.9 ± 0.3 2.4 ± 0.5 2.1 ± 0.4 1.8 ± 0.2 2.1 ± 0.4 1.8 ± 0.3
Fasting HGP, μmoL/min.kg 29.5 ± 0.6 39.1 ± 6.3 36.3 ± 2.3# 41.6 ± 3.6 47.1 ± 4.4 38.5 ± 2.8
Fasting glucose oxidation, dpm/μL6 5 ± 95 2 ± 12 55 ± 98 5 ± 78 6 ± 47 0 ± 5
GIR, μmoL/min.kg 26.3 ± 2.6 26.6 ± 4.1 36.9 ± 4.2 26.7 ± 4.5 33.9 ± 3.9 60.2 ± 5.2#
Plasma insulin during hyperinsulinemic clamp, ng/mL 9.1 ± 0.6 10.9 ± 1.5 8.6 ± 0.6 12.2 ± 0.7 12.4 ± 1.2 14.3 ± 1.6
Hyperinsulinemic glucose uptake, μmoL/min.kg 28.4 ± 1.9 32.1 ± 3.2 39.9 ± 2.8# 40.7 ± 3.7 46.4 ± 2.8 61.1 ± 2.7#
Hyperinsulinemic glucose production, μmoL/min.kg 3.6 ± 1.6 6.02 ± 2.8 2.7 ± 3 13.9 ± 1.2 12.8 ± 1.6 0.96 ± 5.0
Hyperinsulinemic glucose oxidation∗,d p m / μL 184 ± 14 181 ± 10 187 ± 12 219 ± 15 192 ± 8.5 203 ± 13
Skeletal muscle glucose uptake, μmoL/g tissue 0.53 ± 0.1 0.50 ± 0.10 0.56± 0.05 0.51 ± 0.04 0.48 ± 0.04 0.73 ± 0.06#
Heart glucose uptake, μmoL/g tissue 3.0 ± 0.6 4.4 ± 1.3 5.3 ± 1.6 1.8 ± 0.2 2.2 ± 0.2 4.6 ± 0.7∗
Visceral adipose glucose uptake, μmoL/g tissue 0.55 ± 0.06 0.49 ± 0.07 0.74 ± 0.08 0.67 ± 0.13 0.50 ± 0.21 1.1 ± 0.2
Epididemal adipose glucose uptake, μmoL/g tissue 0.47 ± 0.1 0.38 ± 0.08 0.51 ± 0.06 0.33 ± 0.02 0.43 ± 0.07 0.48 ± 0.09
∗Measured 2h after clamp initiation.
ob/ob mice and protein tyrosine phosphatase-1B (PTP-1B)
knockout mice [21]. The sustained reduction in glucose
levels also resulted in improvements in HbA1c.
We initiated our studies in transgenic mice overexpress-
ing human Epo. A metabolic phenotype was observed in
these mice, as fasting blood glucose levels were markedly
reduced relative to the wild-type controls (85.0 ± 11.4
(wt) versus 49.0 ± 7.7 (Epo transgenics) mg/dL, unpub-
lished data). However, the extremely high hematocrit levels
achieved in these mice (>80%) made it technically challeng-
ing to continue metabolic studies in these animals. Katz et al.
were able to complete similar studies showing that tg6 mice
overexpressing human EPO had reduced levels of glucose
and improvements in HbA1c [21].
We chose instead to conduct a hyperinsulinemic-eugly-
cemic clamp study in DIO mice. We monitored the eﬀect
of CNTO 530 on glucose uptake and hepatic glucose pro-
duction in mice fed a high-fat diet for 14 weeks prior to
treatment. In addition, we measured tissue-speciﬁc glucose
uptake in skeletal and cardiac muscle, liver and adipose
tissue. As expected, CNTO 530 increased hemoglobin and
decreased fasting blood glucose fourteen days following
IV administration. In addition, insulin sensitivity was also
improvedatthistime,asindicatedbyasigniﬁcantincreasein
the rate of glucose infusion required to maintain euglycemia
in the CNTO 530-treated animals. Analysis of both hepatic
glucose production and glucose uptake by peripheral tissues
demonstrated that the improvement in insulin sensitivity
was largely due to CNTO 530-mediated enhancement of
insulin-stimulated glucose uptake in skeletal muscle and
heart. CNTO 530 did not aﬀect glucose oxidation suggesting
that CNTO 530 may activate nonoxidative mechanisms of
glucose utilization in skeletal muscle and heart. The eﬀectsof
CNTO530onglucosemetabolismwerearesultofEporecep-
tor signaling as similar improvements were observed in DIO
mice treated with epoetin-α or darbepoetin-α. Epoetin-α or
darbepoetin-α was dosed at levels that induced comparable
increases in hematocrit relative to CNTO 530. Mice treated
with these EpoR agonists also exhibited improved glucose
tolerance but the time course of the eﬀect was shorter and
the increase in glucose tolerance was not nearly as profound
or long-lived as that observed with CNTO 530.
The mechanism by which Epo receptor agonists improve
glucose metabolism is still unclear in both rodents and
humans. Unfortunately, our data does not help to clarify
whether the eﬀect of Epo receptor agonists on glucose
metabolism is linked solely to hematopoiesis. For example,
there is a signiﬁcant increase in hemoglobin in response
to a 0.3 mg/kg dose of CNTO 530 at day 7 (Figure 2(c))
but minimal eﬀect on glucose tolerance (Figure 2(b))
and the glucose tolerance eﬀect persists through day 28
(Figure 2(b)), at which time the hemoglobin is back to
baseline (Figure 2(c)). In addition, while epoetin-α and
darbepoetin-α increased hemoglobin similar to CNTO 530
(day 5 CNTO 530 0.3mg/kg Hct 60%, Epo 0.1mg/kg Hct
58%, Darbe 0.03mg/kg Hct 58%), they had a reduced eﬀect
on glucose tolerance (Figure 4(b)).
One possible mechanism for the improved glucose
tolerance is Epo receptor signaling in striated (skeletal and
cardiac) muscle. In our study, skeletal and cardiac muscle
each showed increased glucose uptake during the clamp
study (Table 1). Both skeletal [22] and cardiac [23]m u s c l e
have been shown by immunohistochemistry to express sar-
colemmal Epo receptors. We conﬁrmed the presence of the
receptor on rat cardiomyocytes by confocal microscopy and
used RT-PCR to show expression of EpoR mRNA in skeletal
muscle of DIO mice (data not shown). Thus CNTO 530
may interact directly with sarcolemmal Epo receptors and
induce a signaling cascade that increases insulin sensitivity
and glucose utilization in these tissues.Experimental Diabetes Research 9
Other studies support a role for skeletal muscle Epo
receptorsignalinginthemetaboliceﬀectsofEpoadministra-
tion. A recent study demonstrated that mice overexpressing
murine Epo were protected against diet-induced obesity
[24]. For this study, doxycycline-dependent transgenic Epo
over-expression was established in the right tibialis cranialis
muscle in mice. Both Epo-expressing and contralateral mus-
cles from these mice exhibited hypertrophy and increased
vascularization. Further, the muscles had increased capacity
tooxidizepalmitatecomparedtocontrolmuscles.Inanother
study, muscle-speciﬁc transgenic expression of Akt1 resulted
in a phenotype which included muscle ﬁber hypertrophy,
resistance to diet-induced obesity and improved glucose
tolerance [25]. EpoR signaling activates Akt through STAT5
and PI3 kinase [26] so one possible explanation for our
data is that CNTO 530 is activating Akt1 in skeletal muscle,
and thus improving glucose utilization. In this regard, PI3
kinase/Akt activation is an essential step for insulin-induced
GLUT4 translocation and subsequent glucose uptake in
skeletal muscle [27].
4. Conclusion
In conclusion, the present study demonstrates that admin-
istration of a single dose of the novel Epo receptor agonist
CNTO 530 to diet-induced obese mice results in improved
glucose tolerance and insulin sensitivity. The increased
glucose tolerance resulted at least in part from increased
uptake of glucose by skeletal and cardiac muscle. The molec-
ular mechanism responsible for translating Epo receptor
signaling into improved glucose tolerance remains elusive.
However, CNTO 530 could represent a novel therapeutic
mechanismoftype2diabetes,providingthatthedrugcanbe
dosed at a level that provides the beneﬁcial metabolic eﬀects
without a risk of substantially increasing hematocrit.
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